atai Life Sciences: Psychedelics, Mental Health, and Drug Development with Founder and Chairman Christian Angermayer
In this episode, hosts Katie Perry and Austin Hankwitz explore atai Life Sciences with Founder and Chairman Christian Angermayer, covering its mission and the rise of mental health issues. Together, they discuss the current state of psychedelic regulation, atai’s drug development phases, how retail investors should approach Atai post-product launch, and the company’s go-to-market strategy.
$ATAI
00:00:00 START
00:01:20 What is atai Life Sciences?
00:08:55 The prevailing theory on the rapid rise of mental health issues
00:15:50 Regulatory bodies’ openness to collaborating with atai
00:17:58…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.